Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Mood Disorders, Antipsychotics, and TD

Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss mood disorders, antipsychotics and tardive dyskinesia (TD).
Joseph Goldberg, MD
Roger McIntyre, MD, FRCPC
Released: May 24, 2021

In this episode, Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss tardive dyskinesia (TD), mood disorders, and antipsychotics. They review current clinical considerations and assessments, including whether antipsychotic prescriptions for mood disorders have increased, if patients with mood disorder are at higher risk for TD and why, and when and how to use an AIMS exam, even in telepsychiatry. They also review the evidence base for VMAT2 inhibitors in TD, what nonevidence-based treatments healthcare professionals should avoid, and how to choose between the 2 VMAT2 inhibitors.  

Presenters:

Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Joseph Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant provided by
Neurocrine Biosciences

Related Content

Podcast with Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, on current clinical assessment and diagnosis of tardive dyskinesia in practice from Clinical Care Options (CCO)

Leslie Citrome, MD, MPH Joseph P. McEvoy, MD Released: June 11, 2021

Clinical Care Options (CCO) commentary by Rifaat S. El-Mallakh, MD, on the differential diagnosis of tardive dyskinesia

Rif S. El-Mallakh, MD Released: June 8, 2021

Clinical Care Options (CCO) commentary by Joseph P. McEvoy, MD, on the assessment of tardive dyskinesia via telepsychiatry

Joseph P. McEvoy, MD Released: May 4, 2021

Learn the latest about personalized treatment of patients with tardive dyskinesia.

John M. Kane, MD Jonathan M. Meyer, MD Released: April 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue